← ANALYST RATINGS · TIPRANKS
Avalyn Pharma Inc (AVLN): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $60.00, the highest $60.00, the lowest $60.00. The average is +153.6% from the last price of $23.66.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $60.00 | Buy | +153.6% | Initiated | 02.10.26on TipRanks 08:00 | +1.8%next day −4.6% · 5 days −9.6% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $52.00 | Buy | +119.8% | Reiterated | 13.08.26on TipRanks 10:45 | −2.8%next day +7.5% · 5 days +3.5% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $53.00 → $57.00+7.5% | Buy | +140.9% | Assigned | 13.08.26on TipRanks 07:55 | −2.8%next day +7.5% · 5 days +3.5% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $51.00 | Buy | +115.6% | Initiated | 26.05.26on TipRanks Jun 3 21:15 | −8.1%next day +0.5% · 5 days −4.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Avalyn Pharma Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $54.50 at a price of $28.49 (+91.3%); now: $56.33 at $23.66 (+138.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Avalyn Pharma Inc
- CEO: Lyn Baranowski
- Employees: 55
- 105 W First St. Boston, Boston, MA, 02127, US
- www.avalynpharma.com
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 155 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗